How have NBY shares performed in 2024?

NovaBay Pharmaceuticals' stock was trading at $0.1802 at the beginning of 2024. Since then, NBY stock has decreased by 53.4% and is now trading at $0.0840. View the best growth stocks for 2024 here .

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 718,800 shares, an increase of 519.1% from the March 15th total of 116,100 shares. Based on an average daily trading volume, of 3,570,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.5% of the shares of the company are short sold. View NovaBay Pharmaceuticals' Short Interest .

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its earnings results on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals's stock reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS) , Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , Bionano Genomics (BNGO) , Heat Biologics (HTBX) , iBio (IBIO) , Matinas BioPharma (MTNB) , Novan (NOVN) , ADMA Biologics (ADMA) and Vaxart (VXRT) .

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free NBY Stock Alerts

$0.08

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.08
▼
$0.09
50-Day Range: N/A
52-Week Range: $0.07
▼
$1.95

Volume: 3.46 million shs
Average Volume: 3.47 million shs
Market Capitalization: $353,640.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest

Get NovaBay Pharmaceuticals alerts:

NovaBay Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.88
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.54) to ($0.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.42 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for NovaBay Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
2.45% of the float of NovaBay Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NovaBay Pharmaceuticals has recently increased by 519.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NovaBay Pharmaceuticals does not currently pay a dividend.
Dividend Growth
NovaBay Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NBY.

2.7

News and Social Media Coverage

News Sentiment
NovaBay Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NovaBay Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for NBY on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NovaBay Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NBY Stock News Headlines

April 17, 2024 | finance.yahoo.com

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

April 17, 2024 | markets.businessinsider.com

Buy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue Performance

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 27, 2024 | finance.yahoo.com

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript

March 27, 2024 | finance.yahoo.com

Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call

March 15, 2024 | barrons.com

NovaBay Pharmaceuticals Inc.

March 14, 2024 | markets.businessinsider.com

NovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick Facts

March 13, 2024 | markets.businessinsider.com

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 26, 2024 | finance.yahoo.com

NovaBay Pharmaceuticals, Inc. (NBY)

January 30, 2024 | finance.yahoo.com

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

January 29, 2024 | msn.com

Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

January 9, 2024 | finance.yahoo.com

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

December 6, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

November 12, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript

November 9, 2023 | benzinga.com

Recap: NovaBay Pharmaceuticals Q3 Earnings

November 9, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

October 21, 2023 | thestreet.com

NovaBay Pharmaceuticals: CEO Interview

October 11, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

October 2, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

September 11, 2023 | marketwatch.com

NovaBay Pharma Shares Rise 42% After Deal With BioStem Technologies

September 11, 2023 | markets.businessinsider.com

NovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova Allograft

September 11, 2023 | benzinga.com

Why NovaBay Pharmaceuticals Stock Is Blasting Higher

September 11, 2023 | msn.com

NovaBay stock soars 86% on optic allograft product deal

September 11, 2023 | marketwatch.com

NovaBay to Commercialize BioStem Technologies' Amniotic Tissue Allograft

September 11, 2023 | finance.yahoo.com

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

See More Headlines

Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:NBY
CUSIP: N/A
CIK: 1389545
Web: novabay.com
Phone: (510) 899-8800
Fax: 510-474-1577
Employees: 29
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($9.9465)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,610,000.00
Net Margins: -79.70%
Pretax Margin: -79.70%
Return on Equity: -146.20%
Return on Assets: -69.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.85
Quick Ratio: 1.25

Sales & Book Value

Annual Sales: $14.40 million
Price / Sales: 0.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.53 per share
Price / Book: 0.05

Miscellaneous

Outstanding Shares: 4,210,000
Free Float: 4,160,000
Market Cap: $353,640.00
Optionable: Not Optionable
Beta: 2.82

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Justin M. Hall Esq. (Age 46)
President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
Comp: $364.95k

Key Competitors

View All Competitors

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed in 2024?: NovaBay Pharmaceuticals' stock was trading at $0.1802 at the beginning of 2024. Since then, NBY stock has decreased by 53.4% and is now trading at $0.0840.
View the best growth stocks for 2024 here.
Are investors shorting NovaBay Pharmaceuticals?: NovaBay Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 718,800 shares, an increase of 519.1% from the March 15th total of 116,100 shares. Based on an average daily trading volume, of 3,570,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.5% of the shares of the company are short sold.
View NovaBay Pharmaceuticals' Short Interest.
How were NovaBay Pharmaceuticals' earnings last quarter?: NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its earnings results on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.
When did NovaBay Pharmaceuticals' stock split?: NovaBay Pharmaceuticals's stock reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).
How do I buy shares of NovaBay Pharmaceuticals?: Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:NBY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

NovaBay Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

NBY Stock Price History

NBY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NBY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™